Theme: Clinical Research Year: 2022
Elimination of hepatitis C (HCV) among people who inject drugs requires continued efforts toward
universal treatment for patients living with HIV/HCV coinfection. Despite progress, treatment uptake
remains incomplete. We aimed to understand provider and clinic staff attitudes toward treating
HIV/HCV co-infected people who currently inject drugs, and what provider-based interventions might
Interviews were conducted with 11 primary care providers who treat patients with HIV/HCV coinfection
at two academic medical centers in New York City, along with 14 other clinical staff, including nurses and
practice managers. Recordings were transcribed and coded thematically using a codebook based on the
Providers reported seeing an average of 51 patients with HIV and three patients with HIV/HCV
coinfection per month. Providers were generally willing to offer HCV treatment to patients currently
using drugs, with only one provider indicating that they might be unwilling to do so. Nearly every
provider cited concerns about medication adherence, and three cited concerns for HCV reinfection.
Providers endorsed the utility of in-clinic care managers and social workers, as well as the local syringe
exchange, in caring for difficult-to-reach patients. Notably, clinical staff stated the difficulty of retaining
individuals in care who are currently using methamphetamines, when compared to other substances.
Providers at two academic medical centers generally expressed willingness to treat HCV in people living
with HIV who are currently using drugs despite perceived barriers. Re-infection remained a concern
despite guidelines suggesting that this should not preclude treatment, suggesting opportunity for
further education. Participant opinions on the difficulty of treating HCV in methamphetamine users
suggest a benefit for specific training in the care of people who use stimulants. These challenges of
healthcare delivery are especially urgent in the context of the COVID-19 pandemic, during which drug
overdose deaths have surged.
Disclosures of Interest:
Funding for the current study was provided by a research grant paid to Columbia University from Gilead
Sciences Inc. Drs Kapadia and Marks have also received unrelated research grants paid to their
institution from Gilead Sciences Inc.